Skip to main content
SpringerLink
Log in

Aspirin, NSAIDs and colorectal cancer—what do the epidemiological studies show and what do they tell us about the modus operandi?

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

A large number of observational epidemiological studies show that regular use of aspirin and other NSAID's is associated with a reduction in the risk of developing both colorectal adenomas and cancer. Furthermore, the prodrug sulindac appears clinically to be able to reduce and reverse the growth of existing polyps in familial adenomatous polyposis (FAP). For aspirin and NSAID's the dose, duration of effect and length of protection seen after cessation remain to be fully established. The available data for aspirin suggest that doses higher than those needed for heart disease prevention are required. It is also likely that the drug needs to be taken continuously for a number of years. With regards to randomised controlled trials to evaluate chemopreventive strategies there are so far only limited data available. The only trial reported to date found no effect but employed a relatively low dose of 325 mg of aspirin every other day and the randomised intervention period was relatively short (5 years). Further trials of intermediate endpoints (adenomas) are currently underway in the UK and USA and are employing higher doses of aspirin. Randomised clinical studies of sulindac have been more encouraging demonstrating that it is a useful drug for therapeutic applications in FAP patients. Its relatively greater side effects, however, prevent its consideration for primary chemoprevention. The mechanisms by which NSAID's act are still sought. Strategies for possible primary and secondary chemoprevention in humans also require evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Morson BC. The polp-cancer sequence in the large bowel. Proceedings of the Royal Society of Medicine 1974; 67: 451–457.

    Google Scholar 

  2. Muto T, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975; 36: 2251–2270.

    Google Scholar 

  3. Morson BC. The evolution of colorectal carcinoma. Clinical Radiobiology 1984; 35: 425–431.

    Google Scholar 

  4. Lofti AM, Spencer RJ, Llstrup DM, et al. Colorectal polyps and the risk of subseqent carcinomas. Mayo Clinic Proceedings 1986; 61: 337–343.

    Google Scholar 

  5. Jass JR. Do all colorectal carcinomas arise in preexisting adenomas? World Journal of Surgery 1989; 13: 45–51.

    Google Scholar 

  6. Konishi F, Morson BC. Pathology of colorectal adenomas: A colonoscopic survey. Journal of Clinical Pathology 1982; 35: 830–841.

    Google Scholar 

  7. O'Brian MJ, Winawer SJ, Sauber AG, et al. The national polp study: Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 24: 83–87.

    Google Scholar 

  8. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83–87.

    Google Scholar 

  9. Bennett A, De Tacca M. Protaglandins in human colonic carcinoma. Gut 1975; 16: 409.

    Google Scholar 

  10. Kune GA, Kune S and Watcon LF. Colorectal cancer risk, colonic illnesses, operations, and medicaitons: Case control results from the Melbourne Colorectal Cancer Study. Can Res 1988; 48: 4399–4404.

    Google Scholar 

  11. Thun MJ, Mohan M, Namboodiri BS, et al. Aspirin use and reduced risk of fatl colon cancer. N Engl J Med 1991; 325: 1593–1596.

    Google Scholar 

  12. Logan RF. Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inlammatory drugs on colorectal adenomas: Case control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993; 307; 285–289.

    Google Scholar 

  13. Thun MJ. Aspirin, NSAIDs, and digestive tract cancers. Cancer and Metastasis Reviews 1994; 13: 269–277.

    Google Scholar 

  14. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal antiinflammatory drugs, eicosanoids and colorectal cancer prevention. Colorectal Neoplasia, Part 1: The Scientific Basis for Current Management 1996; 25: 773–791.

    Google Scholar 

  15. Weiss HA, Forman D. Aspirin, Non-steroidal antiinflammatory drugs and protection from colorectal cancer: A review of the epidemiological evidence. Scand J Gastroenterol 1996; 31Suppl 220: 137–141.

    Google Scholar 

  16. Dubois RN, Smalley WE. Cyclooxygenase, NSAIDs and colorectal cancer. J Gastroenterol 1996; 31: 898–906.

    Google Scholar 

  17. Giardiello FM, Offerhaus GJA, DuBois RN. The Role of Nonsteroidal Anti-inflammatory drugs in colorectal cancer prevention. European Journal of Cancer 1995; 31A: 1071–1076.

    Google Scholar 

  18. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997; 100: 1325–1329.

    Google Scholar 

  19. Stewart BW, McGregor D, Kliehuis P. Principles of chemoprevention. IARC Sci. Pub. No. 139, Lyon France, 1996.

  20. IARC Handbooks of Cancer Prevention. Volume 1—Nonsteroidal anti-inflammatory drugs. International Agency for Research on Cancer, Lyon, 1997.

  21. Gann PH. Manson JE, Glynn RJ, et al. Low dose aspirin and incidence of colorectal tumours in a randomized trial. J Natl Cancer Inst 1993; 85: 1220–1224.

    Google Scholar 

  22. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use in risk of chronic diseases: A cohort study in the elderly. BMJ 1989; 229: 1247–1250.

    Google Scholar 

  23. Paganini-Hill A, Hsu G, Ross RK, et al. Aspirin use and incidence of large-bowel cancer in a Colifornia retirement commuity (correspondence). J Natl Cancer Inst 1991; 83: 1182–1183.

    Google Scholar 

  24. Paganini-Hill A. Apirin and colorectal cancer: The Leisure World cohort revisited. Prev Med 1995; 24: 113–115.

    Google Scholar 

  25. Suh O, Mettlin C, Petrelli J. Aspirin use, cancer and polyps of the large bowel. Cancer 1993; 72: 1171–1177.

    Google Scholar 

  26. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. New Engl J Med 1995; 333: 609–614.

    Google Scholar 

  27. Peleg II, Mailbach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394–399.

    Google Scholar 

  28. Reeves MJ, Newcomb PA, Trentham-Dietz A, et al. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epiremiol Bio Prev 1996; 5: 955–960.

    Google Scholar 

  29. Smalley W, Wayne RA, Daugherty J, et al. Non-aspirin nonsteroidal anti-inflammatory drug use and colorectal cancer: A population-based study in the elderly. Gastrointestinal Oncology 1998; A681.

  30. Giardiello FM. Sulindac and polyp regression. Cancer and Metastasis Review 1994; 13: 279–283.

    Google Scholar 

  31. Hucker HB, Stauffer Sr C, White SD, et al. Physiologic disposition and metabolic fate of a nuew anti-inflammatory agent, cis-5-Floro-2-methyl-1-{p-(methylsulfinyl)-benzylindenyl}-indene-3-acetic acid in the rat, dog, rhesus monkey and man. Drug Metoblism and Disposition 1973; 1: 721–736.

    Google Scholar 

  32. Rigau J, Pique J, Rubio E, et al. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952–954.

    Google Scholar 

  33. Hirota C, Iida M, Aoyagi K, et al. Effect of indomethacin suppositories on rectal polyposis in patients with fammilial adenomatous polyposis. Cancer (Phila) 1996; 78: 1660–1665.

    Google Scholar 

  34. Hixson LJ, Earnest DL, Fennerty MB, et al. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993; 88: 1652–1656.

    Google Scholar 

  35. DiSario JA, Alberts DS, Tietze CC, et al. Sulindac induces regression and prevents progression of sporadic colorectal adenomas (abstr). Gastroenterology 1997; 112: A555.

    Google Scholar 

  36. Stryker SJ, Wolff GB, Culp CE, et al. Natural history of untreated colonic polyps. Gastroenterology 1987; 93(5): 1009–1013.

    Google Scholar 

  37. Stürmer T, Glynn RJ, Lee I-Min, et al. Aspirin use and colorectal cancer: Post-trial follow-up data from the physicians health study. Ann Intern Med 1998; 128: 713–720.

    Google Scholar 

  38. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635–639.

    Google Scholar 

  39. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 11313–11316.

    Google Scholar 

  40. Nonsteroidal anti-inflammatory agents. In: Mc Evoy G, ed. AHFS Drug Information. Bethesda MD: The American Society of Hospital Pharmacists, Inc., 1993: 1201–1205.

  41. Eberhart, CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. J Gastroenterol 1994; 107: 1183–1188.

    Google Scholar 

  42. Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. J Gastroenterol 1997; 113: 1992–1998.

    Google Scholar 

  43. Elder DJE, Paraskeva C. NSAIDs to prevent colorectal cancer: A question of sensitivity. J Gastroenterol 1997; 113: 1999–2008.

    Google Scholar 

  44. Jouzeau, JY, Terlain B, Abid A, et al. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997; 53(4): 563–582.

    Google Scholar 

  45. Elder DJ, Halton DE, Hague A, et al. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cycloozygenase-2 (cox-2)-selective nonsteroidal antiinflammatory drug: Independence from cox-2 protein expression. Clinical Cancer Research 1997; 3: 1679–1683.

    Google Scholar 

  46. Featherstone C. Aspirin for bowel cancer: An old friend finds a new role. Lancet 1997; 350: 418.

    Google Scholar 

  47. Gupta RA, DuBois. Aspirin, NSAIDs, and colon cancer prevention: Mechanisms? Gastroenterology 1998; 114: 1095–1100.

    Google Scholar 

  48. Greenberg ER, Baron JA, Freeman DH Jr, et al. Reduced risk of large-bowel adenomas among aspirin users. The polyp prevention study group. J Natl Cancer Inst 1993; 85: 912–916.

    Google Scholar 

  49. Martinez ME, McPherson RS, Levin B, et al. Aspirin and other nonsteroidal anti-inflammatory drugs an risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Bio Prev 1995; 4: 703–707.

    Google Scholar 

  50. Sandler RS, Galanko JC, Murray SC, et al. Aspirin and Nonsteroidal antiinflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114: 441–447.

    Google Scholar 

  51. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: Nonsteroidal anitiinflammatory drugs reduce the risk of large bowel cancer. J Natl Cancer Inst 1991; 83: 355–358.

    Google Scholar 

  52. Muller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer. A case control study among veterans. Dig Dis Sci 1994; 39: 2480–2484.

    Google Scholar 

  53. La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer 1997; 7(5): 675–677.

    Google Scholar 

  54. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–246.

    Google Scholar 

  55. Thun MJ, Calle EE, Namboodiri MM, et al. Aspirin use, cancer, and polyps of the large bowel. Cancer Res 1993; 53: 1322–1327.

    Google Scholar 

  56. Schreinemachers DM, Everson RB. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–246.

    Google Scholar 

  57. Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 44–48.

    Google Scholar 

  58. Muscat JE, Stallman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847–1854.

    Google Scholar 

  59. Peleg II, Lubin MF, Cotsonis GA, et al. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996; 41: 1319–1326.

    Google Scholar 

  60. Gridley G, McGlaughlin JK, Ekbom A, et al. Incidence of cancer among patients with reheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307–311.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Public Health Medicine & Epidemiology, Queens Medical Centre, Nottingham, NG7 2UH, UK

    K. R. Muir & R. F. A. Logan

Authors
  1. K. R. Muir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. F. A. Logan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muir, K.R., Logan, R.F.A. Aspirin, NSAIDs and colorectal cancer—what do the epidemiological studies show and what do they tell us about the modus operandi?. Apoptosis 4, 389–396 (1999). https://doi.org/10.1023/A:1009603522855

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009603522855

Search

Navigation